Roche: efficacy of Evrysdi in spinal muscular atrophy
At the end of the fifth year, 91% of treated children were alive, 81% without permanent ventilation, and 59% could sit without support.
Seven children could stand and some could walk with support. Evrysdi helped maintain or improve motor skills, swallowing and tube-free feeding, the laboratory points out.
Adverse events fell by 66% between the first and last years, with fewer hospitalizations.
Evrysdi is the only non-invasive oral treatment for SMA, developed by Roche in collaboration with the SMA Foundation and PTC Therapeutics.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction